Bull Flag Stocks
RARE is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Price & Overview
NASDAQ:RARE • US90400D1081
Current stock price
24.1 USD
-0.96 (-3.83%)
At close:
24.2 USD
+0.1 (+0.41%)
Pre-Market:
The current stock price of RARE is 24.1 USD. Today RARE is down by -3.83%. In the past month the price increased by 18.89%. In the past year, price decreased by -36.73%.
RARE Key Statistics
52-Week Range18.29 - 42.37
Current RARE stock price positioned within its 52-week range.
1-Month Range18.29 - 26.19
Current RARE stock price positioned within its 1-month range.
- Market Cap
- 2.37B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.84
- Dividend Yield
- N/A
RARE Stock Performance
Today
-3.83%
1 Week
-1.91%
1 Month
+18.89%
3 Months
-0.45%
Longer-term
6 Months -28.12%
1 Year -36.73%
2 Years -43.35%
3 Years -44.81%
5 Years -78.41%
10 Years -64.36%
RARE Stock Chart
RARE Stock Screens
RARE currently appears in the following ChartMill screener lists.
RARE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to RARE. When comparing the yearly performance of all stocks, RARE is a bad performer in the overall market: 85.26% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
RARE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RARE. RARE may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RARE Earnings
On February 12, 2026 RARE reported an EPS of -1.29 and a revenue of 207.00M. The company missed EPS expectations (-15.82% surprise) and beat revenue expectations (3.03% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported-$1.29
Revenue Reported207M
EPS Surprise -15.82%
Revenue Surprise 3.03%
RARE Forecast & Estimates
26 analysts have analysed RARE and the average price target is 52.34 USD. This implies a price increase of 117.19% is expected in the next year compared to the current price of 24.1.
For the next year, analysts expect an EPS growth of 21.03% and a revenue growth 12.73% for RARE
Analysts
Analysts83.85
Price Target52.34 (117.18%)
EPS Next Y21.03%
Revenue Next Year12.73%
RARE Groups
Sector & Classification
RARE Financial Highlights
Over the last trailing twelve months RARE reported a non-GAAP Earnings per Share(EPS) of -5.84. The EPS increased by 7.89% compared to the year before.
Income Statements
Revenue(TTM)673.00M
Net Income(TTM)-575.00M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.53% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%7.19%
Sales Q2Q%25.55%
EPS 1Y (TTM)7.89%
Revenue 1Y (TTM)20.13%
RARE Ownership
Ownership
Inst Owners99.15%
Shares98.32M
Float94.82M
Ins Owners3.31%
Short Float %12.04%
Short Ratio5.17
RARE Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RARE
Company Profile
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,371 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Company Info
IPO: 2014-01-31
ULTRAGENYX PHARMACEUTICAL IN
60 Leveroni Ct
Novato CALIFORNIA 94949 US
CEO: Emil D. Kakkis
Employees: 1371
Phone: 14154838800
ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ
What does ULTRAGENYX PHARMACEUTICAL IN do?
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,371 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Can you provide the latest stock price for ULTRAGENYX PHARMACEUTICAL IN?
The current stock price of RARE is 24.1 USD. The price decreased by -3.83% in the last trading session.
What is the dividend status of ULTRAGENYX PHARMACEUTICAL IN?
RARE does not pay a dividend.
What is the ChartMill technical and fundamental rating of RARE stock?
RARE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for RARE stock?
26 analysts have analysed RARE and the average price target is 52.34 USD. This implies a price increase of 117.19% is expected in the next year compared to the current price of 24.1.
Can you provide the growth outlook for ULTRAGENYX PHARMACEUTICAL IN?
The Revenue of ULTRAGENYX PHARMACEUTICAL IN (RARE) is expected to grow by 12.73% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?
The outstanding short interest for ULTRAGENYX PHARMACEUTICAL IN (RARE) is 12.04% of its float.